The GLAGOV trial further substantiated the benefits of PCSK9 inhibition, where the addition of evolocumab to statins in patients with coronary disease resulted in regression of atherosclerotic plaque, as evidenced by intravascular ultrasonography—another testament to the efficacy of achieving lower LDL-C levels [40]. This evidence concerns the gene PCSK9 and coronary artery disorder.